ASCO Genitourinary Symposium

Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

February 15th 2025, 10:52pm

Article

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma

February 15th 2025, 10:36pm

Article

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC

February 15th 2025, 8:54pm

Article

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.

Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment

February 15th 2025, 8:43pm

Article

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.

FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC

February 15th 2025, 8:04pm

Article

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

February 15th 2025, 6:00pm

Article

Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.

Padcev Significantly Improves OS in Real-World Urothelial Carcinoma

February 15th 2025, 5:25pm

Article

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.

Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions

February 14th 2025, 9:32pm

Article

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma

February 14th 2025, 7:30pm

Article

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.

Padcev May Be Safe in Older Patients With Bladder Cancer

February 14th 2025, 6:35pm

Article

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.